Advertisement
Pharmaceutical Companies
Subscribe to Pharmaceutical Companies

The Lead

In Alzheimer's Mice, Memory Restored With Cancer Drug

April 1, 2015 1:01 pm | by Yale University | News | Comments

Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug.

Teva Launches Exforge Generic

March 31, 2015 11:33 am | News | Comments

Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan)...

Teva Buying Auspex for $3.2 Billion

March 30, 2015 12:54 pm | by The Associated Press | News | Comments

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion...

Genentech Announces Plans to Expand Hillsboro Facility

March 26, 2015 3:26 pm | News | Comments

Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for...

View Sample

FREE Email Newsletter

Shire and Cincinnati Children's Establish Rare Disease Research Collaboration

March 26, 2015 8:17 am | News | Comments

The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise.

AstraZeneca Joins Genomics England Consortium

March 26, 2015 8:03 am | News | Comments

AstraZeneca today announced that it has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project.

AstraZeneca to Collaborate With the Harvard Stem Cell Institute in Diabetes

March 25, 2015 8:45 am | News | Comments

AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

Advertisement

Merck Board OKs Additional $10B Stock Buyback Plan

March 25, 2015 8:15 am | News | Comments

Merck & Co. says its board approved the repurchase of up to $10 billion more of its stock. The company said that amount will be added to the $1.7B remaining available for repurchase under a prior authorization.

Lycera Announces Milestone in Merck Collaboration

March 25, 2015 8:04 am | News | Comments

Lycera Corp. today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.

Multiple Canadian Provinces to Provide Public Funding for Gilead's Harvoni™

March 24, 2015 8:26 am | News | Comments

Gilead Sciences Canada today announced that multiple provinces will provide public access to Harvoni ™ (ledipasvir/sofosbuvir), the first once-daily, single tablet regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults.

BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases

March 24, 2015 8:16 am | News | Comments

Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.

ImmunoGen Lands Licensing Deal with Takeda

March 23, 2015 4:08 pm | by The Associated Press | News | Comments

Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.

Advertisement

Teva Announces New Head of Business Development, Strategy and Innovation

March 23, 2015 4:05 pm | News | Comments

Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.

Biogen Shares Soar on Optimistic Alzheimer's Drug Study Data

March 23, 2015 8:18 am | by The Associated Press | News | Comments

Biogen released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.

Biogen Idec Becomes Biogen

March 23, 2015 8:15 am | News | Comments

Effective today, Biogen Idec is known simply as Biogen. The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet needs.

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

March 23, 2015 8:07 am | News | Comments

Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.

FDA Panel Backs Glaxo Inhaler for Adults, Not Adolescents

March 20, 2015 8:39 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents.

Advertisement

Biogen Idec Releases Alzheimer's Drug Data

March 20, 2015 8:07 am | by The Associated Press | News | Comments

Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.

Study: Prevnar Vaccine Slashed Serious Infections in Elderly

March 19, 2015 8:33 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in adults 65 and older found it protected most of them against dangerous infections in the bloodstream and other sterile body areas.

Daiichi Sankyo Signs Agreement with AstraZeneca to Co-Commercialize MOVANTIK in the US

March 19, 2015 8:18 am | News | Comments

Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.

Phase III Study with IMBRUVICA Combination Demonstrates Significant Delay in Disease Progression

March 17, 2015 8:45 am | News | Comments

Janssen has announced that a pre-planned interim analysis of the Phase 3 HELIOS study investigating the combination of IMBRUVICA plus bendamustine and rituximab (BR) versus placebo plus BR in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, showed the trial has met its primary endpoint.

Galapagos Regains Rights to GLPG1690, Ends Alliance with Janssen

March 17, 2015 8:29 am | News | Comments

Galapagos NV has announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies.

Indiana Medicaid Recovers $126,000 in Lawsuit Settlement

March 17, 2015 8:05 am | News | Comments

Indiana's Medicaid program will receive more than $126,000 from a drug manufacturer that filed false claims to Medicaid and other federally funded health care programs.

Valeant Boosts Offer for Salix Pharma to About $11.11B

March 16, 2015 8:29 am | News | Comments

Valeant is raising its offer for Salix Pharmaceuticals to about $11.11 billion, heating up a bidding fight for the company.

Merck's Sugammadex Dealt Another Setback

March 16, 2015 8:06 am | News | Comments

The company said Friday that the Food and Drug Administration has canceled a March 18 meeting to review sugammadex, which is designed to help patients "wake up" after surgical anesthesia.

Studies Boost Hopes for New Class of Cholesterol Medicines

March 16, 2015 8:02 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.

Ad Industry Group Recommends That Little Remedies Stop Cold, Sore Throat Claims

March 13, 2015 2:22 pm | by Andy Szal, Digital Reporter | News | Comments

The National Advertising Division--an industry regulatory agency administered by the Council of Better Business Bureaus--investigated Prestige Brands Holdings' Little Remedies products following a complaint by Pfizer.

GSK Completes Sale of Half Its Stake in Aspen Pharmacare

March 13, 2015 8:36 am | News | Comments

GlaxoSmithKline has announced the completion of the disposal of half of its 12.4% shareholding in Aspen. Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital.

Pfizer Reports Results From A Phase IV Study Evaluating LYRICA® for Adolescents with Fibromyalgia

March 13, 2015 8:07 am | News | Comments

Pfizer has announced top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading